Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Expeditors International of Wshngtn Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.04 (market cap $29.60B), while Expeditors International of Wshngtn Inc trades at $181.88 (market cap $23.04B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Expeditors International of Wshngtn Inc pays a 0.91% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | EXPD | |
|---|---|---|
Market Cap | $29.60B | $23.04B |
Sector | Health | Industrials |
52-Week High | $491.22 | $182.80 |
52-Week Low | $205.48 | $113.13 |
Enterprise Value | $27.56B | $22.57B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
EXPD trades at $179.00, near its 52-week high, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings of $2.03 per share, beating estimates by 20%, driven by airfreight and customs demand. Revenue growth is steady, with 2026 projected at $12.0B, though ocean freight contraction poses a headwind. Analyst consensus is a Hold with a $181.14 price target, indicating limited near-term upside.
Outlook: EXPD's earnings momentum and expanding AOG services offer growth potential, but high valuation (P/E 25.79) and reliance on tariff policies heighten risk. Investors should weigh robust profitability (ROE 42.6%) against cyclical freight pressures and analyst caution. The stock is fairly valued, with gains contingent on sustaining airfreight strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
